We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 7 for:    S1400

S1400B Lung-MAP: Taselisib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02785913
First Posted: May 30, 2016
Last Update Posted: July 18, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Southwest Oncology Group
  Purpose
This phase II trial studies how well taselisib (GDC-0032) works in treating patients with stage IV squamous cell lung cancer that has come back after previous treatment. This is a sub-study that includes all screened patients positive for the phosphoinositide 3-kinase (PI3K) biomarker. PI3K can cause tumor cells to grow more quickly. Taselisib may decrease the activity of PI3K and may be able to shrink tumors.

Condition Intervention Phase
Recurrent Squamous Cell Lung Carcinoma Stage IV Squamous Cell Lung Carcinoma Other: Laboratory Biomarker Analysis Drug: Taselisib Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)

Resource links provided by NLM:


Further study details as provided by Southwest Oncology Group:

Primary Outcome Measures:
  • Objective Response Rate (ORR) (confirmed and unconfirmed, complete and partial) (Design #2, Phase II) [ Time Frame: Up to 3 years ]
    The investigational therapy arm will be judged to have provided sufficient evidence to proceed to the Phase III component if the ORR is at least 25%. Response rates and associated confidence intervals will be calculated.


Secondary Outcome Measures:
  • DoR among patients who achieve a CR or PR by RECIST 1.1 (Design #2, Phase II) [ Time Frame: Up to 3 years ]
    Estimated using the method of Kaplan-Meier. The Brookmeyer-Crowley method will be used to calculate confidence intervals for median DoR.

  • OS with investigational therapy (Design #2, Phase II) [ Time Frame: Up to 3 years ]
    A stratified (using randomization stratification factors) log-rank test will be used to test the primary hypotheses related to OS comparing the two treatment arms at the levels specified. A Cox PH model will be used to estimate the hazard ratios and associated confidence intervals.

  • PFS with investigational therapy (Design #2, Phase II) [ Time Frame: Up to 3 years ]
    A stratified (using randomization stratification factors) log-rank test will be used to test the primary hypotheses related to PFS comparing the two treatment arms at the levels specified. A Cox PH model will be used to estimate the hazard ratios and associated confidence intervals.

  • Severity of toxicities associated with investigational therapy (Design #2, Phase II) [ Time Frame: Up to 3 years ]
    Analysis of toxicities will be performed using a chi-square or Fisher's exact test, as appropriate.


Other Outcome Measures:
  • Screen success rate, monitored by the percentage of screened patients that register to a therapeutic sub-study [ Time Frame: Up to 3 years ]
  • Treatment arm randomization acceptance rate, monitored by the percentage of patients that receive at least one dose of the treatment they are randomized to [ Time Frame: Up to 3 years ]

Estimated Enrollment: 59
Study Start Date: June 2014
Estimated Study Completion Date: June 2020
Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm I (GDC-0032)
Patients receive taselisib PO daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Other: Laboratory Biomarker Analysis
Correlative studies
Drug: Taselisib
Given PO
Other Name: GDC-0032
Experimental: Arm III (taselisib re-registration)
Patients in Arm II eligible for crossover re-registration receive taselisib PO on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Other: Laboratory Biomarker Analysis
Correlative studies
Drug: Taselisib
Given PO
Other Name: GDC-0032

Detailed Description:

PRIMARY OBJECTIVES:

I. To evaluate if there is sufficient evidence to continue to the phase III component by evaluating the objective response rate (ORR) for PI3K Genentech (GNE)-positive patients registered to S1400B treated with GDC-0032. (Phase II) II. If the study meets the criteria specified in S1400, the study will be amended to include a follow-on randomized phase III trial.

SECONDARY OBJECTIVES:

I. To evaluate investigator-assessed progression free survival (IA-PFS) and overall survival (OS) in both the subset of patients defined to be PI3K GNE-positive and in the entire S1400B (PI3K Foundation Medicine [FMI] positive) study population treated with GDC-0032. (Phase II) II. To evaluate ORR in the entire S1400B (PI3K FMI positive) study population treated with GDC-0032 to evaluate the duration of response (DoR) both in GNE positive and FMI positive. (Phase II) III. To evaluate the DoR both in the entire S1400B PI3K FMI positive study population and in GNE positive patients treated with GDC-0032 who achieve a complete response (CR) or partial response (PR) (confirmed and unconfirmed) by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1. (Phase II) IV. To evaluate the frequency and severity of toxicities associated with GDC-0032. (Phase II)

TRANSLATIONAL MEDICINE OBJECTIVES:

I. To identify additional predictive tumor/blood biomarkers that may modify response or define resistance to the GDC-0032 beyond the chosen biomarker for biomarker-driven sub-studies.

II. To identify potential resistance biomarkers at disease progression. III. To establish a tissue/ blood repository from patients with refractory squamous cell carcinoma (SCCA) of the lung.

OUTLINE: As of 12/18/2015, patients are assigned to Arm I.

ARM I: Patients receive taselisib orally (PO) daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

ARM II (CLOSED TO ACCRUAL 12/18/2015): Patients receive docetaxel intravenously (IV) on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Upon progression, patients may be eligible to re-register to Arm III.

ARM III: Patients in Arm II eligible for re-registration receive taselisib orally (PO) on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, all patients are followed up every 6 months for the first 2 years and then at the end of the year 3 from date of sub-study/re-registration.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must meet all SCREENING/PRE-SCREENING and SUB-STUDY REGISTRATION COMMON ELIGIBILITY CRITERIA as specified in S1400: Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
  • Patients must be assigned to S1400B
  • Hemoglobin A1c (HbA1c) < 7% obtained within 28 days prior to sub-study registration
  • Fasting glucose < 125 mg/dL obtained within 28 days prior to sub-study registration
  • Patients must not have type I or II diabetes that requires anti-hyperglycemic medication
  • Patients must not have active or a history of small or large intestine inflammation such as Crohn's disease or ulcerative colitis
  • Patients must not require daily supplemental oxygen
  • Patients must be able to take oral medications; patients may not have any impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of GDC-0032 (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)
  • Patients must not be taking, nor plan to take while on protocol treatment and for 14 days post the last dose of study treatment, drugs, herbal supplements or foods that are known to be strong/moderate cytochrome p450, family 3, subfamily A, polypeptide 4 (CYP3A4) substrates
  • Patients must also be offered participation in banking for future use of specimens
  • STEP 2 TO GDC-0032 RE-REGISTRATION:
  • Patients must have progressed on arm 2 (docetaxel) of this sub-study
  • Patients must not have received any prior systemic therapy (systemic chemotherapy, immunotherapy or investigational drug) within 21 days prior to step 2 re-registration; patients must have recovered (< grade 1) from any side effects of prior therapy
  • Patients must have measurable disease documented by computed tomography (CT) or magnetic resonance imaging (MRI); the CT from a combined PET/CT may be used to document only non-measurable disease unless it is of diagnostic quality; measurable disease must be assessed within 28 days prior to step 2 re-registration; pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease; non-measurable disease must be assessed within 42 days prior to step 2 re-registration; all disease must be assessed and documented on the baseline tumor assessment form; patients whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease (in the opinion of the treating investigator) prior to registration
  • Patients must have a CT or MRI scan of the brain to evaluate for central nervous system (CNS) disease within 42 days prior to step 2 re-registration; patient must not have leptomeningeal disease, spinal cord compression or brain metastases unless: (1) metastases have been locally treated and have remained clinically controlled and asymptomatic for at least 14 days following treatment, AND (2) patient has no residual neurological dysfunction and has been off corticosteroids for at least 1 day prior to re-registration
  • Patients must not be planning to receive any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment; concurrent use of hormones for non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptable
  • Absolute neutrophil count (ANC) >= 1,500/mcl obtained within 28 days prior to step 2 re-registration
  • Platelet count >= 100,000 mcl obtained within 28 days prior to step 2 re-registration
  • Hemoglobin >= 9 g/dL obtained within 28 days prior to step 2 re-registration
  • Serum bilirubin =< institutional upper limit of normal (IULN); for patients with liver metastases, bilirubin must be =< 5 x IULN obtained within 28 days prior to step 2 re-registration
  • Either alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 2 x IULN within 28 days prior to step 2 re-registration (if both ALT and AST are done, both must be < 2 IULN); for patients with liver metastases, either ALT or AST must be =< 5 x IULN (if both ALT and AST are done, both must be =< 5 x IULN)
  • HbA1c < 7% obtained within 28 days prior to step 2 re-registration
  • Fasting glucose < 125 mg/dL obtained within 28 days prior to step 2 re-registration
  • Serum creatinine =< the IULN OR measured or calculated creatinine clearance >= 50 mL/min
  • Patients must have Zubrod performance status of 0-1 documented within 28 days prior to step 2 re-registration
  • Patients must not have any grade III/IV cardiac disease as defined by the New York Heart Association Criteria (i.e., patients with cardiac disease resulting in marked limitation of physical activity or resulting in inability to carry on any physical activity without discomfort), unstable angina pectoris, and myocardial infarction within 6 months, or serious uncontrolled cardiac arrhythmia
  • Patients must not have documented evidence of acute hepatitis or have an active or uncontrolled infection
  • Patients with a known history of human immunodeficiency virus (HIV) seropositivity: must have undetectable viral load using standard HIV assays in clinical practice; must have cluster of differentiation (CD)4 count >= 400/mcL; must not require prophylaxis for any opportunistic infections (i.e., fungal, mycobacterium avium complex [mAC], or pneumocystis pneumonia [PCP] prophylaxis); must not be newly diagnosed within 12 months prior to re-registration
  • Prestudy history and physical exam must be obtained within 28 days prior to re-registration
  • No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years
  • Patients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures
  • As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
  • Patients with impaired decision-making capacity are eligible as long as their neurological or psychological condition does not preclude their safe participation in the study (e.g., tracking pill consumption and reporting adverse events to the investigator)
  • Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02785913


  Show 1111 Study Locations
Sponsors and Collaborators
Southwest Oncology Group
National Cancer Institute (NCI)
Investigators
Principal Investigator: Vassiliki Papadimitrakopoulou Southwest Oncology Group
  More Information

Responsible Party: Southwest Oncology Group
ClinicalTrials.gov Identifier: NCT02785913     History of Changes
Other Study ID Numbers: S1400B
NCI-2014-01379 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
S1400B ( Other Identifier: SWOG )
S1400B ( Other Identifier: CTEP )
U10CA180888 ( U.S. NIH Grant/Contract )
First Submitted: May 25, 2016
First Posted: May 30, 2016
Last Update Posted: July 18, 2017
Last Verified: July 2017

Additional relevant MeSH terms:
Carcinoma
Lung Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases